Toya S Pratt1, Anne M Suskind2. 1. Kaiser Permanente East Bay-University of California San Francisco, 275 MacArthur Blvd, Oakland, CA, 94618, USA. 2. University of California, San Francisco, 400 Parnassus Avenue, Box 0738, San Francisco, CA, 94143, USA. anne.suskind@ucsf.edu.
Abstract
PURPOSE OF REVIEW: This review will highlight our current understanding of age-related changes in bladder function and propose important clinical considerations in the management of overactive bladder (OAB) specific to older women. RECENT FINDINGS: Frailty, functional and cognitive impairment, multimorbidity, polypharmacy, estrogen deficiency, and remaining life expectancy are important clinical factors to consider and may impact OAB symptom management in older women. Third-line therapies, particularly PTNS, may be preferable over second-line therapy in some cases. Due to the complexity within this population, the standard treatment algorithms may not be applicable, thus a broader, more holistic focus is recommended when managing OAB in older women.
PURPOSE OF REVIEW: This review will highlight our current understanding of age-related changes in bladder function and propose important clinical considerations in the management of overactive bladder (OAB) specific to older women. RECENT FINDINGS: Frailty, functional and cognitive impairment, multimorbidity, polypharmacy, estrogen deficiency, and remaining life expectancy are important clinical factors to consider and may impact OAB symptom management in older women. Third-line therapies, particularly PTNS, may be preferable over second-line therapy in some cases. Due to the complexity within this population, the standard treatment algorithms may not be applicable, thus a broader, more holistic focus is recommended when managing OAB in older women.
Authors: Anne M Suskind; Kathryn Quanstrom; Shoujun Zhao; Mark Bridge; Louise C Walter; John Neuhaus; Emily Finlayson Journal: Urology Date: 2017-05-11 Impact factor: 2.649
Authors: Stasa D Tadic; Derek Griffiths; Werner Schaefer; Andrew Murrin; Becky Clarkson; Neil M Resnick Journal: Neurourol Urodyn Date: 2012-03-30 Impact factor: 2.696
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Ling-Hong Tseng; Alex C Wang; Yao-Lung Chang; Yung-Kuei Soong; L Keith Lloyd; Yet-Jane Ko Journal: Neurourol Urodyn Date: 2009 Impact factor: 2.696
Authors: Katrin Jekel; Marinella Damian; Carina Wattmo; Lucrezia Hausner; Roger Bullock; Peter J Connelly; Bruno Dubois; Maria Eriksdotter; Michael Ewers; Elmar Graessel; Milica G Kramberger; Emma Law; Patrizia Mecocci; José L Molinuevo; Louise Nygård; Marcel Gm Olde-Rikkert; Jean-Marc Orgogozo; Florence Pasquier; Karine Peres; Eric Salmon; Sietske Am Sikkes; Tomasz Sobow; René Spiegel; Magda Tsolaki; Bengt Winblad; Lutz Frölich Journal: Alzheimers Res Ther Date: 2015-03-18 Impact factor: 6.982
Authors: A Rebecca Meekins; Susan K Murphy; Carole Grenier; Zhiqing Huang; Megan S Bradley; Cindy L Amundsen; Jennifer Wu; Nazema Y Siddiqui Journal: Neurourol Urodyn Date: 2019-04-22 Impact factor: 2.696